Kornimate/medical-research-clean huggingface dataset:
physiotherapy in knee osteoarthritis

Conditions: Knee Osteoarthritis

Summary: osteoarthritis symptoms can be managed with non-drug treatments such as patient education, exercise or weight loss interventions. cryotherapy is one of the effective method to reduce joint inflammation, pain and improve function. another method is joint mobilization, which can also reduce pain and improve function. based on this theory, it was hypothesized that cryotherapy will have better effect on pain and the quality of life, whereas joint mobilization will be more effective on knee function. the aim of the study was to compare the effects of different physiotherapy methods on pain, knee joint function and quality of life in individuals with osteoarthritis.

study included 63 participants with knee osteoarthritis. all subjects were randomly assigned to one of 3 groups: exercise group (n=21), exercise + cryotherapy group (n=21), or exercise + joint mobilization group (n=21). vas scale was used to assess the pain, quality of life was evaluated with short form 36 health survey questionnaire (sf-36) questionnaire, knee ranges of motion were measured using a goniometer, strength of the muscles was assessed on the oxford 5 point scale, the western ontario and mcmaster universities arthritis index (womac) was used to evaluate knee osteoarthritis. all the participants received 30 intervention sessions.

Eligibility criteria:
inclusion criteria: * stage ii of the knee oa; * affected knee joint; * pain of at least 3 points on the vas. exclusion criteria: * severe cardiovascular disease; * oncological disorders; * allergy to cold / cold intolerance; * impaired lower limbs blood circulation; * fear of confined spaces; * pregnancy or lactation.

Keywords: knee function womac quality of life joint mobilization physiotherapy
physiopathological and therapeutic value of microrna in the progression of carotid artery plaques: carotid protocol and microrna

Conditions: Carotid Arteries

Summary: molecular analysis of the atheroma plaque. screening for a novel biomarker of carotid status.


Eligibility criteria:
inclusion criteria: * adults having to undergo carotid thromboendarteriectomy * social security coverage * provision of study information * consent to participation. exclusion criteria: * previous carotid artery surgery * refusal to participate in the study * or inability to give consent.

Keywords: micro-rna
acute respiratory failure and covid-19 in real life

Conditions: Coronavirus Infections; Respiratory Failure; Ventilator Lung

Summary: in december 2019 a new kind of virus was identified in china as the responsible of severe acute respiratory syndrome (sars) and interstitial pneumonia. severe acute respiratory syndrome coronavirus 2 (sars-cov-2) quickly spread around the world and in february 2020 became a pandemia in europe. no pharmacological treatment is actually licensed for the sars-cov2 infection and at the current state of art there is a lack of data about the clinical management of the coronavirus 2019 disease (covid-19). the aim of this observational study is to collect the data and the outcomes of covid-19 patients admitted in the h. sacco respiratory unit treated according to the standard operating procedures and the good clinical practice.

all consecutive adult covid-19 patients admitted to our respiratory unit will be enrolled. all demographic, anthropometric, laboratory, radiological, clinical and microbiological data will be collected and analyzed according to the primary and secondary outcomes (see the dedicated section). during the hospitalization, patients will be treated according to the standard operating procedure of our respiratory unit, such as arterial gas analysis, rx, pharmacological treatment, ventilation. this study is purely observational and no randomization will be performed. after discharge, patients a 7 days, 30 days and 6 months follow up will be assessed.

Eligibility criteria:
inclusion criteria: * patients that can give written or oral informed consent * patients with microbiological diagnosis (i.e. rhinopharyngeal swab) of sars-cov2 infection exclusion criteria: * severe cognitive impairment * absolute contraindication to non invasive ventilation or cpap therapy * rhinopharyngeal swab negative for sars-cov2

Keywords: sars acute respiratory failure cpap therapy non invasive ventilation gas exchange
evaluation of safety and efficacy of using venus freeze™ (mp)2 v2 system for wrinkles rhytides and cellulite treatment

Conditions: Wrinkled Structure; Circumference Reduction

Summary: skin aging is a multifactorial process involving the 3 layers of the skin: epidermis, dermis and hypodermis. radio-frequency (rf) devices have been used for many years for a variety of surgical applications. the energy delivery systems of these established monopolar devices used a 'conductive coupling' delivery system in which energy is concentrated at the periphery of the electrode. venus concept has developed the venus freeze (mp)2 v2 system for wrinkles, rhytides and temporary cellulite and circumference reduction treatments. while treating wrinkles rhytides and cellulite, the treatments creates enough thermal effect to induce collagen remodeling with no ablative thermal damage in the epidermis or dermis.


Eligibility criteria:
inclusion criteria: * healthy males and females age 30 and up * subjects with fitzpatrick 4 to 9 degrees of elastosis * subject able to comprehend and give informed consent for participation in this study * subject must commit to all treatments and follow-up visits * subject must sign the informed consent form exclusion criteria: * subjects with implanted pacemakers, arrhythmias or any other severe known heart disorder * subjects with any implantable metal device in the treatment area * subjects on any medication that would affect the characteristic of the skin (medical or hormonal), such as "accutane", within the past 6 months or photosensitizing medications * subjects that have had any other invasive or non invasive method of skin therapy or hair removal performed in the past 9 months (in the treated area) subjects who are scheduled or planned for any other invasive or non invasive method of skin therapy or hair removal in the treated area at the period of the study * subjects who have any form of malignant skin cancer on the treatment area * subjects with history of keloid formations or hypertrophic scarring * pregnant or lactating subjects * subjects with epilepsy or severe migraines * subjects with permanent makeup/ tattoo/ body piercing (in the treated area) * subjects with any infection / abscess / dermatitis/ pains in treatment target area. * subjects who suffer from autoimmune disorders or diabetes * subjects with clotting disorders * subjects are suffering from psychiatric disorders and treated with psychiatric medications. * subject is suffering extreme general weakness. * subject objects to the study protocol * concurrent participation in any other clinical study * physician objection

Keywords: wrinkles rhytides cellulite circumference reduction
magnetismm-3: study of elranatamab (pf-06863135) monotherapy in participants with multiple myeloma who are refractory to at least one pi, one imid and one anti-cd38 mab

Conditions: Multiple Myeloma

Summary: the purpose of the study is to evaluate whether single-agent elranatamab (pf-06863135) can provide clinical benefit in participants with relapsed/refractory multiple myeloma. elranatamab is a bispecific antibody: binding of elranatamab to cd3-expressing t-cells and bcma-expressing multiple myeloma cells causes targeted t-cell-mediated cytotoxicity.


Eligibility criteria:
inclusion criteria: * diagnosis of multiple myeloma (imwg criteria, rajkumar et al, 2014) * measurable disease, as defined by at least 1 of the following: 1. serum m-protein \>0.5 g/dl by spep 2. urinary m-protein excretion \>200 mg/24 hours by upep 3. serum immunoglobulin flc≥10 mg/dl (≥100 mg/l) and abnormal serum immunoglobulin kappa to lambda flc ratio * refractory to at least one imid * refractory to at least one pi * refractory to at least one anti-cd38 antibody * relapsed/refractory to last anti-myeloma regimen * cohort a: has not received prior bcma-directed therapy * cohort b: has received prior bcma-directed therapy (adc or car t cells) * ecog performance status ≤2 * resolved acute effects of any prior therapy to baseline severity or ctcae grade ≤1 * not pregnant and willing to use contraception exclusion criteria: * smoldering multiple myeloma * active plasma cell leukemia * amyloidosis * poems syndrome * stem cell transplant within 12 weeks prior to enrollment * active hbv, hcv, sars-cov2, hiv, or any active, uncontrolled bacterial, fungal, or viral infection * any other active malignancy within 3 years prior to enrollment, except for adequately treated basal cell or squamous cell skin cancer, or carcinoma in situ. * previous administration with an investigational drug within 30 days or 5 half-lives preceding the first dose of study intervention used in this study (whichever is longer)

Keywords: myeloma multiple myeloma relapsed multiple myeloma refractory multiple myeloma pf-06863135 bcma bispecific bispecific antibody bcma-cd3 bispecific elranatamab magnetismm-3
objective evaluation of patients with palmar hyperhidrosis submitted to two levels of sympathectomy: t3 and t4.

Conditions: Hyperhidrosis; Quality of Life

Summary: compare the results obtained with video-assisted sympathectomy performed in two distinct levels ganglionic (third versus fourth thoracic ganglion) for the treatment of palmar hyperhidrosis, through a blind randomized clinical trial using an objective method to measure the sweat before and after the operation.

currently, the treatment of choice for treating palmar hyperhidrosis (ph) is video-assisted thoracic sympathectomy (vats) . this minimally invasive technique has been well standardized and provides adequate results with low morbidity. the main side effect of vats is compensatory hyperhidrosis (ch). this is present in most cases and is considered the greatest cause of dissatisfaction. to reduce the risk of ch, various studies have been conducted to compare different levels of ganglion resection. these studies have been based on subjective quantification of sweating (assessment of sweating reported by patients) and on the application of quality-of-life questionnaires. recently, tests for the objective evaluation of sweating have been developed to quantify sweating among patients with various diseases, including ph. so far, there have not been any studies comparing the long-term results of thoracic sympathectomy on the third ganglion (g3) versus the fourth ganglion (g4)with objective evaluation to quantify sweating. the present study was prospective, randomized and blinded, with the objective of comparing the results from vats at two different resection levels: g3 versus g4. all the patients were followed over a one-year period, and their palmar sweating was quantified using a portable device (vapometer) to measure transepidermal water loss (tewl). in addition, ch was evaluated by applying a specific quality-of-life questionnaire.

Eligibility criteria:
inclusion criteria: * being determined to accomplish the procedure, because such a statement depends on the level of discomfort suffered by the patient. * absence of previous thoracic surgery. * concordance with the completion of informed consent. * preoperative normal, including chest radiograph, electrocardiogram, blood count, sodium, potassium, urea, creatinine, glucose and thyroid hormones. exclusion criteria: * patients with bmi\> 25. * pregnancy. * younger than 15 and more than 45 years. * heart disease that may contraindicate the procedure (congestive heart failure, coronary insufficiency, cardiac arrhythmias, symptomatic, acute myocardial infarction, etc.). * acute infections or chronic. * bleeding disorder. * neoplasms. * inflammatory diseases of pulmonary or pleural.

Keywords: hyperhidrosis thoracic sympathectomy objective measurement of sweat
il8 monitoring and its correlation with 251-gene polymorphism

Conditions: Sepsis; Systemic Inflammatory Response Syndrome

Summary: one hundred eighty critically ill african adult intensive care patients divided into two groups, eighty septic critically ill patients (sepsis group) while, eighty non-septic critically ill patients (sirs) group. admission serum il-8 was measured in both sepsis and sirs groups. il-8 (-251a/t) polymorphism was detected in sepsis and sirs groups.

a total of one hundred eighty african patients (97men and 83 women) were included in the study. eighty patients developed septic complication during icu stay (sepsis group). eighty patients were critically ill without evidence of infectious organism (sirs group). patients received anti-inflammatory drugs or corticosteroids before admission, who had immunosuppressive illness, who had chronic organ failure; who had received massive blood transfusion; those with radiation therapy, previous organ transplantation were excluded from the study. at admission, the patient's age, sex, height and weight were recorded. these data include the following: clinical status; sequential organ failure assessment (sofa) score; temperature; heart rate; respiratory rate; blood pressure; central venous pressure; laboratory analysis (complete blood count, blood urea nitrogen, blood sugar, serum sodium, potassium, calcium, aspartate aminotransferase, alanine aminotransferase, prothrombin time, albumin and crp) and arterial blood gas analysis. routine cultures of blood, urine and suspected sites were obtained to determine the presence of infection. we attempted to maintain the patient hemoglobin level at 10-12g/dl and central venous pressure at 8-12 cmh2o. if needed, blood products, intravascular fluid replacement and inotropic and/or vasopressor agents were administered. each day the attending physician in the icu evaluated all the study patients for sepsis, severe sepsis, or septic shock.

Eligibility criteria:
inclusion criteria: adults patients with clinical diagnosis of sepsis or systemic inflammatory response syndrome. exclusion criteria: patients received anti-inflammatory drugs or corticosteroids before admission, patients who had immunosuppressive illness ie. aids, patients with chronic liver failure, patients with renal failure, patients with respiratory failure ; patients received massive blood transfusion; patients with radiation therapy, patients with organ transplantation .

Keywords: serum il-8 il8 polymorphism critically ill patients
fabry cardiomyopathy: identification of early myocardial structural and tissue abnormalities using multiparametric mri

Conditions: Fabry Disease

Summary: this study will evaluate whether cardiac mri t1 and t2 mapping improves our ability to detect early abnormalities in the heart in patients with fabry disease and identify patients at increase risk of adverse events.

fabry disease is an inherited disorder that affects many organs in the body, including the heart. men and women are both affected, with average life expectancy reduced by 10-20 years. the heart muscle can become thick and scarred in over half of patients, eventually resulting in heart failure, abnormal rhythm and death. the focus of this study will be on improving the detection of early heart disease before irreversible damage has occurred in order to improve patient outcomes. it is hypothesized that new cardiac mri techniques called t1 and t2 mapping will improve the ability to detect early abnormalities in the heart. early detection of cardiac disease may enable a personalized treatment approach, potentially improving patient outcomes. the results of the study will identify which patients might benefit from early initiation of treatment to prevent bad outcomes in the future by using cardiac mri to identify those at higher risk.

Eligibility criteria:
inclusion criteria: * fabry disease; * age ≥ 18 years. exclusion criteria: * history of myocardial infarction; * contraindication to mri.

Keywords: fabry disease fabry cardiomyopathy cardiac mri cmr t1 mapping t2mapping
the effect of different lining strategies on amalgam restorations

Conditions: Post-operative Pain; Dental Caries

Summary: the aim of this research is to compare the clinical outcome of amalgam restorations placed in conjunction with three different lining protocols, each of which represents a different therapeutic concept.

patients attending one of eight, united kingdom general dental practitioners for a new restoration in a posterior tooth will be recruited and informed consent obtained. each dentist will place 20 amalgam restorations either unlined (control), or lined with calcium hydroxide cement, rmgi cement, or sealed with a resin bonding agent (total - 640). pre-operative radiographs and pulp testing will be performed and measurement of cavity size to assess the remaining dental thickness. the pulp status and symptoms will be recorded at 6, 12, and 24 months. post-operative sensitivity will be recorded by the patient at 1, 3, 7, 14 and 28 days using a visual analogue scale and diary. the dentists will be trained and calibrated to use united states public health service criteria and the condition of the restoration will be assessed at 12 and 24 months. for each lining option, one product and one admixed amalgam will be provided for use by all the dentists. training and instruction will be given on the application of the liners and on amalgam condensation to increase standardisation. the collected data will be assessed to identify any association between the outcome variables and the pre-treatment tooth condition or lining material used using logistic regression (α=0.05).

Eligibility criteria:
inclusion criteria: * healthy adults over 18 years * presence of one or more carious cavities extending beyond the outer 1/3 of the dentine * able to give valid consent to participate in study * willing to receive an amalgam restoration in a target tooth * teeth free from pain * teeth with vital pulps exclusion criteria: * replacement restorations * psychiatric conditions or medication which may affect pain perception. * cavities limited to the outer ⅓ of dentine. * teeth with existing symptoms or sensitivity * patients under 18 years * non-vital teeth * allergy or idiosyncratic reaction to the study materials * inability to return for review * fractured or cracked teeth * pregnancy or breast-feeding
mechanisms of diuretic resistance in heart failure, aim 2

Conditions: Heart Failure

Summary: randomized placebo-controlled, double-blind, double-dummy, crossover design testing combinations placebo/placebo, bendroflumethiazide/placebo, amiloride/placebo, and bendroflumethiazide/amiloride added to bumetanide.

this study will employ a randomized placebo-controlled, double-blind, double-dummy, crossover design testing combinations placebo/placebo, bendroflumethiazide/placebo, amiloride/placebo, and bendroflumethiazide/amiloride added to bumetanide. patients will be co-enrolled in this study and an ancillary study for administration of bendroflumethiazide. administration of bendroflumethiazide will take place under an ancillary protocol.

Eligibility criteria:
inclusion criteria: 1. clinical diagnosis of hf 2. no plan for titration/change of heart failure medical or device therapies during the study period. 3. absence of non-elective hospitalizations in the previous 2 weeks 4. at optimal volume status by symptoms, exam, and dry weight. 5. serum potassium ≤ 5.0 mmol/l 6. serum sodium ≥ 130 meq/l 7. age \> 18 years 8. hemoglobin ≥8 g/dl 9. objective evidence of diuretic resistance to a 10mg bumetanide challenge, defined as: 1. fena \<10% and total sodium output \<150mmol and 2. at least one of the following criteria: 1. chronic home furosemide dose \> or equal to 80mg furosemide equivalents daily 2. egfr \< 60ml/min 3. serum chloride \<100mmol/l 4. fena \<5% and total sodium output \<75mmol on the 2 hour screening exclusion criteria: 1. gfr \<20 ml/min/1.73m2 using the ckd-epi equation or use of renal replacement therapies 2. use of any non-loop type diuretic in the last 7 days or 5 half lives, with the exclusion of low dose aldosterone antagonist (e.g., spironolactone or eplerenone ≤50 mg). examples of non-loop diuretics include but may not be limited to acetazolamide (oral or iv, not ophthalmic), metolazone, hctz, chlorthalidone, chlorothiazide, indapamide, triamterene, amiloride, finerenone, spironolactone dose \> 50mg day, eplerenone \> 50mg/day, 3. history of flash pulmonary edema requiring hospitalization and treatment with biphasic positive airway pressure or mechanical ventilation or a "brittle" volume sensitive hf phenotype such as an infiltrative or restrictive cardiomyopathy (i.e. amyloid cardiomyopathy, etc). 4. hemoglobin \< 8 g/dl or symptomatic anemia 5. pregnant or breastfeeding 6. inability to give written informed consent or comply with study protocol or follow-up visits 7. chronic urinary retention limiting ability to perform timed urine collection procedures 8. on lithium therapy 9. on pimozide or thioridazine 10. diagnosis of liver failure 11. contraindications or allergy to sulfonamides 12. any contraindication to thiazide diuretic or allergy to thiazide or bendroflumethiazide
tampere traumatic head and brain injury study

Conditions: Traumatic Brain Injury

Summary: tampere traumatic head and brain injury study is a prospective study aiming to explore neuroradiological, neuropsychological, neurological and biochemical aspects of mild traumatic brain injury (mtbi). the main interest is on factors that effect to the outcome after mtbi. the study is conducted in tampere university hospital's emergency department between the 1st of august 2010 and 31st of july 2013.

aims of the study: 1. to improve clinical assessment of mtbi in the acute phase 2. to assemble better knowledge of diffusion tensor imaging as a diagnostic tool in mtbi 3. to improve neuropsychological evaluation of mtbi main focus on psychosocial functioning / outcome / correlates e.g. resilience, ptsd

Eligibility criteria:
inclusion criteria: * who's mtbi criteria * inhabitant of pirkanmaa hospital district * age between 18 and 60 years exclusion criteria: * detrimental alcohol use * drug addiction * chronic neurological disease * earlier brain injury * diagnosed psychiatric disease * hearing or sight deficiency * native language other than finnish
roux-en-y versus billroth ii reconstruction after subtotal gastrectomy in gastric cancer comorbid with type ii diabetes

Conditions: Gastric Cancer; Type 2 Diabetes

Summary: gastric bypass improves glycemic levels in type 2 diabetes. however, the efficacy may be varied by different gastric-small intestine reconstruction used in the procedure. there are reports that roux en y reconstruction may give a better result. the purpose of this study is to compare roux en y and billroth ii reconstruction in patients with gastric cancer comorbid with type 2 diabetes.

type 2 diabetes may cause severe complications such as nephropathy and retinopathy. additionally, it is associated with increased risk for cardiovascular events and diseases. surgical intervention with gastric bypass has been shown to attenuate glycemic levels in obese patient comorbid with type 2 diabetes. however, since gastric bypass is not a standard procedure, surgical protocol including stomach and small intestine reconstruction may be varied. the investigators and others have found that stomach and small intestine reconstruction may affect the efficacy of diabetic treatment. in this study, the investigators will compare the efficacy of billroth ii and roux en y reconstruction on glycemic control in stomach cancer patients with type 2 diabetes. both billroth ii and roux en y are used in stomach-small intestine reconstruction after subtotal gastrectomy. no differences in postoperative outcomes and quality of life have been reported in billroth ii and roux en y reconstruction.

Eligibility criteria:
inclusion criteria: 1. diagnosed with type 2 diabetes 2. diagnosed with gastric cancer exclusion criteria: 1. type 1 diabetes 2. unresectable cancers

Keywords: diabetes gastric cancer gastric bypass